MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has been selected to present significant findings from its latest Alzheimer’s study at the Alzheimer’s Association International Conference® 2024 (AAIC®). The conference will be held from July 28 to August 1 in Philadelphia and online.
Dr. Cheng Fang, Senior VP of Research & Development at Annovis Bio, will present alongside Kathleen A. Welsh-Bohmer, Ph.D., Professor in Psychiatry and Neurology at Duke University, and Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. Their 45-minute oral presentation, scheduled for July 31, will delve into the efficacy and safety of Buntanetap, a promising treatment for mild Alzheimer’s disease (AD).
Key Findings and Presentation Details
The presentation, titled “Data from Phase 2/3 Clinical Study in Mild to Moderate Alzheimer’s Disease,” will highlight the potential of Buntanetap as a breakthrough treatment. It will cover the drug’s performance in both APOE4 carriers and non-carriers, two critical groups in Alzheimer’s research. This comprehensive session aims to provide an in-depth look at how Buntanetap can address the complex needs of Alzheimer’s patients.
“We look forward to sharing the details of our Phase 2/3 results with the scientific community at this prominent conference,” said Dr. Cheng Fang. “We are also grateful for the 45-minute format, which allows us to present our data comprehensively.”
A Game-Changer for Alzheimer’s
The AAIC is a premier global forum for dementia research, drawing scientists worldwide to discuss advancements and foster collaborations. Annovis Bio’s selection to present at this conference marks a significant achievement. It places the company at the forefront of Alzheimer’s research, highlighting its commitment to developing innovative treatments.
Buntanetap’s potential as a treatment could be a game-changer for Alzheimer’s patients. Current treatments offer limited relief, and a breakthrough drug could dramatically improve quality of life for millions. The detailed presentation will allow researchers to scrutinize the findings and potentially build on Annovis Bio’s work.
The Potential of Buntanetap
If Buntanetap proves effective, it could lead to new standards in Alzheimer’s treatment. For patients and families, it offers hope for better management of a debilitating condition. For the medical community, it represents progress in understanding and treating Alzheimer’s.
The conference also provides a platform for Annovis Bio to collaborate with other researchers. These interactions can lead to further innovations and accelerate the development of effective treatments. The publication of the abstract in the online version of Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association will ensure that the findings reach a wide audience, fostering further research and discussion.
Leading the Charge Against Alzheimer’s
Annovis Bio’s presentation at the AAIC 2024 underscores its pivotal role in Alzheimer’s research. By sharing their promising findings on Buntanetap, the company contributes to the global effort to combat Alzheimer’s disease. As the scientific community gathers in Philadelphia and online, all eyes will be on Annovis Bio’s groundbreaking work and its potential to change the landscape of Alzheimer’s treatment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.